Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Children: Thin but Encouraging Evidence

This systematic review and single-arm meta-analysis quantifies the limited pediatric evidence for two newer beta-lactam/beta-lactamase inhibitor combinations, clarifying where they can and cannot be recommended.

📅 Journal publication: Feb 2026 (online Jan 3, 2026) · Last updated: Oct 12, 2026

ceftazidime-avibactamceftolozane-tazobactambeta-lactam/beta-lactamase inhibitormultidrug-resistant Gram-negativecomplicated urinary tract infectioncomplicated intra-abdominal infectionpediatric infectious diseaseantimicrobial stewardshipsystematic reviewmeta-analysis Pediatric Pharmacy

Also in Infectious Disease / Antimicrobials

Background Information

New BL/BLI antibiotics show promise for serious pediatric infections.

Ceftazidime/avibactam and ceftolozane/tazobactam are important in treating severe pediatric infections, which require effective and safe antibiotic options. The meta-analysis shows these novel beta-lactam/beta-lactamase inhibitors (BL/BLI) have promising efficacy and safety profiles in children. While these medications are effective, clinicians should consider resistance patterns and pharmacokinetic data specific to pediatric patients. Novel BL/BLI antibiotics offer promising options for severe infections in children.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Pimenta-de-Souza P, Ramos-Silva A, Sandes V, Portella P, Gouvêa T, Fernandez-Llimos F, Lima EC

Citation: Pimenta-de-Souza P, Ramos-Silva A, Sandes V, et al. Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map. International journal of antimicrobial agents. 2026;67(2):107710. doi:10.1016/j.ijantimicag.2025.107710

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →